CIDP Quality of Life Impact and Unmet Needs

In "CIDP Quality of Life Impact and Unmet Needs," our panel explores the full scope of living with CIDP and the resources available to address its wide-ranging effects. Panelists highlight that while weakness and sensory impairment are the defining features of the disease, pain affects approximately 20% of patients, and fatigue and depression are common but often underappreciated burdens. Experts emphasize that these symptoms are not always attributable to CIDP itself, and that comorbid conditions such as sleep apnea, anemia, and mood disorders should be independently evaluated and treated.

Beyond immunotherapy, the panel advocates for a multidisciplinary management approach that includes physical therapy for balance and strength, occupational therapy for hand function, pain management specialists when needed, and psychological support for depression and mood disorders. Aerobic exercise is highlighted as having published controlled evidence supporting its role in managing fatigue, despite being counterintuitive to many patients. Panelists also recommend connecting patients with patient foundations, such as the GBS/CIDP Foundation, and involving primary care physicians to ensure that comorbid conditions are not overlooked. The diagnostic complexity of CIDP in patients with diabetes is noted as a particular challenge, given that diabetic neuropathy can produce electrodiagnostic findings that mimic CIDP.

The episode closes with a rapid-fire discussion of unmet needs in the field. Panelists call for more effective therapies that go beyond stabilization to meaningfully improve function and quality of life. A strong case is made for earlier diagnosis, with one expert drawing a parallel to clinically isolated syndrome in multiple sclerosis and arguing that by the time current diagnostic criteria are met, significant axonal degeneration has likely already occurred. The development of reliable biomarkers emerges as the most broadly shared priority, encompassing diagnostic biomarkers for earlier and more accurate disease identification, disease activity biomarkers to guide treatment decisions, and biomarkers to predict individual treatment response as newer therapies continue to emerge.

Our next episode, "CIDP Standard of Care Treatment Options and Immunoglobulin Dosing: Insights from the ICE Trial," features panelists providing a high-level overview of current treatment options for CIDP, including corticosteroids, immunoglobulin products, and newer therapies, with a deeper dive into the pivotal ICE study and evolving evidence supporting individualized IVIG dosing protocols.